Berndl
Alfons Berndl, Schaufling DE
Gunther Berndl, Herxheim Am Berg DE
Patent application number | Description | Published |
---|---|---|
20090028938 | DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH | 01-29-2009 |
20090214656 | ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔH | 08-27-2009 |
20090302493 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 12-10-2009 |
20140005204 | ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | 01-02-2014 |
20140087060 | Process For Producing A Solid Dispersion Of An Active Ingredient - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 03-27-2014 |
Gunther Berndl, Herheim Am Berg DE
Patent application number | Description | Published |
---|---|---|
20110311595 | DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH | 12-22-2011 |
Gunther Berndl, Bad Duerkheim DE
Patent application number | Description | Published |
---|---|---|
20120225953 | Self-Emulsifying Active Ingredient Formulation and the Use of this Formulation - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 09-06-2012 |
20140135388 | Self-Emulsifying Active Ingredient Formulation and the Use of This Formulation - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 05-15-2014 |
Gunther Berndl, Herxheim DE
Patent application number | Description | Published |
---|---|---|
20080299203 | Solid Pharmaceutical Dosage Formulation - The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 12-04-2008 |
20110008430 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-13-2011 |
20110015216 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-20-2011 |
20110123652 | SELF-EMULSIFYING ACTIVE SUBSTANCE FORMULATION AND USE OF THIS FORMULATION - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 05-26-2011 |
20120022089 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-26-2012 |
20120202858 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 08-09-2012 |
20130004578 | Solid Pharmaceutical Dosage Formulation - The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 01-03-2013 |
20130072508 | SOLID PHARMACEUTICAL DOSAGE FORM - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 03-21-2013 |
20140179721 | SOLID PHARMACEUTICAL DOSAGE FORM - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 5° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 06-26-2014 |
Gunther Berndl, Bad Durkheim DE
Patent application number | Description | Published |
---|---|---|
20140296336 | SOLID RETARD FORMULATIONS BASED ON SOLID DISPERSIONS - A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation. | 10-02-2014 |
Juergen Berndl, Nandlstadt DE
Patent application number | Description | Published |
---|---|---|
20150288240 | Stator with Phase Insulation for an Electric Machine and Production Method for Such a Stator - The invention relates to a stator for an electric machine, comprising a cylindrical stator body having several stator slots. At least one first coil is inserted into the stator slots for a first phase, where the first coil has a first coil end on at least one face of the stator body. At least one second coil is inserted into the stator slots for a second phase, where the second coil has a second coil end on the at least one face of the stator body. And t least one third coil is inserted into the stator slots for a third phase, where the third coil has a third coil end on the at least one face of the stator body. The stator also comprises at least one molded body for receiving and electrically insulating the coil ends, wherein the molded body extends in a first ring area and a second ring area concentric with respect to the first ring area, on the at least one face of the cylindrical stator body, such that the at least one first coil end is arranged in the first ring area, the at least one third coil end is arranged in the second ring area, and the at least one second coil end is arranged in the first and in the second ring area. | 10-08-2015 |
Jurgen Berndl, Nandlstadt DE
Patent application number | Description | Published |
---|---|---|
20120267349 | JOINING DEVICE FOR NON-POSITIVE JOINING BY MEANS OF A FILLER MATERIAL USING SENSORS - A joining device for a bonded connection by means of a filler material has a feeding device for a wire as the filler material, which is configured to feed the wire during operation of the joining device at a predetermined speed of advance, and a guiding device for an energy beam with at least two partial beams for the melting of the wire. The joining device has a first measuring sensor for detecting a lateral deflection of the wire and a second measuring sensor for detecting a quantity related to the advancement of the wire, wherein the guiding device for the energy beam is connected to the first and the second measuring sensor and configured such that the energy beam is deflected and/or focused in dependence on the output signals of the first and second measuring sensor. | 10-25-2012 |